Kidney function estimating equations: where do we stand?

被引:130
|
作者
Coresh, Josef
Stevens, L. A.
机构
[1] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA
[2] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA USA
来源
关键词
glomerular filtration rate (GFR); GFR estimating equations; GFR estimation; serum creatinine;
D O I
10.1097/01.mnh.0000222695.84464.61
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Estimation of the glomerular filtration rate (GFR) is central to the diagnosis, evaluation and management of chronic kidney disease. This review summarizes recent data on the performance of equations using serum creatinine to estimate the GFR, particularly the Modification of Diet in Renal Disease (MDRD) Study equation. Recent findings During 2005 GFR estimation has received substantial attention with a focus on comparing the MDRD Study equation with the Cockcroft-Gault equation. Several large studies (n > 500) have appeared. Most studies discuss creatinine calibration but few were able to standardize measurements. Studies that did calibrate the creatinine had improved performance. Overall, the MDRD Study equation performed well in populations with a low range of GFR and often outperformed the Cockcroft-Gault equation. Both equations have lower precision in high GFR populations, and the MDRD equation under-estimated the GFR in a number of studies. Efforts are underway to develop improved prediction equations by pooling data across many study populations. Summary Equations for estimating the GFR from serum creatinine are useful for systematic staging of chronic kidney disease. The MDRD Study equation and systematic creatinine assay calibration improve the level of precision and accuracy in many settings. GFR estimates are less useful in the normal range of GFR, however, and are sensitive to the population under study.
引用
收藏
页码:276 / 284
页数:9
相关论文
共 50 条
  • [1] Biomarkers in kidney transplantation: Where do we stand?
    Lopez-Abad, A.
    Piana, A.
    Prudhomme, T.
    Marco, B. Banuelos
    Donmez, M. I.
    Pecoraro, A.
    Boissier, R.
    Campi, R.
    Breda, A.
    Territo, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (06): : 407 - 409
  • [2] Diabetic kidney disease, revisited: where do we stand?
    Cha, Dae Ryong
    [J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2022, 41 : S31 - S32
  • [3] Where do we stand?
    Thompson, ID
    [J]. FORESTRY CHRONICLE, 2003, 79 (03): : 381 - 382
  • [4] Where do we stand?
    不详
    [J]. INTERNATIONAL JOURNAL OF PRODUCTIVITY AND PERFORMANCE MANAGEMENT, 2010, 59 (03) : 79 - 86
  • [5] Where do we stand?
    Catt, Graham
    [J]. AUSTRALIAN VETERINARY JOURNAL, 2008, 86 (07) : N8 - N8
  • [6] WHERE DO WE STAND
    MCMILLAN, B
    [J]. IRE TRANSACTIONS ON INFORMATION THEORY, 1957, 3 (03): : 173 - 174
  • [7] WHERE DO WE STAND?
    Stolper, Gustav
    [J]. HARVARD BUSINESS REVIEW, 1931, 9 (03) : 289 - 298
  • [8] WHERE DO WE STAND
    不详
    [J]. MILITARY MEDICINE, 1961, 126 (01) : 66 - &
  • [9] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    [J]. TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [10] Assessment of Liver Function With MRI: Where Do We Stand?
    Rio Bartulos, Carolina
    Senk, Karin
    Schumacher, Mona
    Plath, Jan
    Kaiser, Nico
    Bade, Ragnar
    Woetzel, Jan
    Wiggermann, Philipp
    [J]. FRONTIERS IN MEDICINE, 2022, 9